Atara Biotherapeutics (NASDAQ:ATRA) Now Covered by Analysts at Rodman & Renshaw

Rodman & Renshaw initiated coverage on shares of Atara Biotherapeutics (NASDAQ:ATRA) in a research note published on Friday,Benzinga reports. The firm issued a buy rating and a $25.00 price target on the biotechnology company’s stock.

Several other equities analysts have also recently issued reports on ATRA. TD Cowen raised shares of Atara Biotherapeutics to a “strong-buy” rating in a research note on Friday, November 29th. Canaccord Genuity Group boosted their price target on shares of Atara Biotherapeutics from $13.00 to $21.00 and gave the stock a “buy” rating in a research note on Wednesday, November 13th. One analyst has rated the stock with a sell rating, two have assigned a hold rating, three have issued a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, Atara Biotherapeutics has a consensus rating of “Moderate Buy” and a consensus target price of $18.75.

Atara Biotherapeutics Stock Up 14.8 %

NASDAQ ATRA opened at $11.40 on Friday. The firm has a market cap of $65.66 million, a P/E ratio of -0.44 and a beta of 0.55. Atara Biotherapeutics has a 52-week low of $6.50 and a 52-week high of $39.50. The business’s 50-day moving average price is $10.80 and its 200 day moving average price is $9.60.

Atara Biotherapeutics (NASDAQ:ATRA) last announced its earnings results on Tuesday, November 12th. The biotechnology company reported ($2.93) earnings per share for the quarter, beating the consensus estimate of ($3.77) by $0.84. The company had revenue of $40.19 million during the quarter, compared to analysts’ expectations of $23.00 million. During the same quarter last year, the business posted ($16.50) earnings per share. As a group, analysts anticipate that Atara Biotherapeutics will post -12.12 earnings per share for the current year.

Hedge Funds Weigh In On Atara Biotherapeutics

Institutional investors and hedge funds have recently made changes to their positions in the stock. Cubist Systematic Strategies LLC purchased a new stake in Atara Biotherapeutics during the second quarter worth about $79,000. Point72 Asia Singapore Pte. Ltd. purchased a new stake in shares of Atara Biotherapeutics during the 2nd quarter worth approximately $53,000. Vestal Point Capital LP grew its holdings in shares of Atara Biotherapeutics by 11.3% in the 3rd quarter. Vestal Point Capital LP now owns 124,677 shares of the biotechnology company’s stock worth $1,014,000 after acquiring an additional 12,677 shares during the period. Geode Capital Management LLC grew its holdings in shares of Atara Biotherapeutics by 9.5% in the 3rd quarter. Geode Capital Management LLC now owns 46,720 shares of the biotechnology company’s stock worth $380,000 after acquiring an additional 4,043 shares during the period. Finally, State Street Corp increased its stake in Atara Biotherapeutics by 52.3% in the 3rd quarter. State Street Corp now owns 22,353 shares of the biotechnology company’s stock valued at $182,000 after purchasing an additional 7,680 shares in the last quarter. 70.90% of the stock is owned by institutional investors and hedge funds.

About Atara Biotherapeutics

Atara Biotherapeutics, Inc engages in the development of transformative therapies for patients with solid tumors, hematologic cancers, and autoimmune diseases in the United States and the United Kingdom. Its lead product includes Tab-cel (tabelecleucel), a T-cell immunotherapy program that is in Phase 3 clinical trials for the treatment of epstein-barr virus (EBV) driven post-transplant lymphoproliferative disease, as well as nasopharyngeal carcinoma.